Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • GSK forms drug...

    GSK forms drug discovery alliance with University of California CRISPR researchers

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-14T12:24:07+05:30  |  Updated On 16 Aug 2021 1:55 PM IST



    British drugmaker GSK said it has struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California, in a boost to its prospects for developing new drugs.


    GlaxoSmithKline, Britain's largest drugmaker, will pay up to $67 million over a five-year period for the new Laboratory for Genomics Research, which will be jointly run with the University of California and led by researchers such as Jennifer Doudna, a co-inventor of the CRISPR gene-editing technology.


    New gene editing tools - with CRISPR/Cas9 as the most prominent example - have thrown the door wide open for rearranging the genetic code much more precisely and at lower costs than previously possible.


    Read Also: GSK Nucala wins USFDA approval for two new self-administration options


    The technology made headlines last year when a Chinese scientist caused outrage with a claim to have "gene-edited" babies, but CRISPR/Cas9 can also be used in medical and agricultural research without interfering with the human germline.


    CRISPR works as molecular scissors that can trim away unwanted pieces of genetic material and replace them with new ones. Easier to use than older techniques, it has quickly become a preferred method of gene editing in research labs.


    The new GSK lab will run tests on various irregularities in the human genome and track the malfunctions they trigger in cells, hoping to gain a clearer understanding of the causes of cancer as well as neurological and immunological diseases.


    "Once we understand how that changes its function, we can think about how to mitigate that functional impairment and normalise the cell, and normalise, hopefully, the patient by just developing a drug that could prevent them from developing the disease," said GSK's Chief Scientific Officer Hal Barron.


    Read Also: GSK sells 6 brands including Savlon antiseptic cream to Stada Pharma


    GSK, which had hired Barron from Alphabet-backed biotech firm Calico in 2017, will become more dependent on its drug development fortunes as it prepares to fold its consumer health business into a joint venture with Pfizer that will be separately listed.


    Automation and heavy-duty computing will allow researchers to analyse hundreds of millions of genetic combinations per experiment at the new lab, Barron added.


    The University of California in February scored a victory in a drawn-out legal battle with the Cambridge, Massachusetts-based Broad Institute over the CRISPR patent application that Doudna filed together with Emmanuelle Charpentier of the University of Vienna in 2012.


    The new lab in San Francisco will include facilities for 24 full-time university employees funded by GSK plus up to 14 full-time GSK staff.


    Read Also: GSK reintroduce incentives for sales representatives


    Other pharma companies are investing in the new method. Bayer and Vertex Pharmaceuticals have independently established collaborations with CRISPR Therapeutics, a biotech firm working on gene therapies.


    For GSK, the California lab project ties in with existing data-driven alliances in genetic research with Alphabet -funded gene testing company 23andMe, or with the UK Biobank, a genetic database project.








    BayerBritish drugmaker GSKcancerCRISPR Cas9CRISPR gene editing technologyCRISPR TherapeuticsGSKGSK labimmunological diseasesJennifer DoudnaneurologicalPfizerUniversity of CaliforniaVertex Pharmaceuticals
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok